Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%

All products: general benefit

Other products in the same Health Canada class (A10AD) — coverage varies; not interchangeable

  • Insulin neutral + isophane human biosynthetic (Novolin ge 30/70): general benefit
  • Insulin aspart + insulin aspart protamine (NovoMix 30 Penfill): general benefit
  • Insulin lispro + insulin lispro protamine (Humalog Mix25): general benefit

Humulin 30/70 · DIN 00795879 · 1000U/10mL · injection suspension-10mL Pk

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Humulin 30/70 · DIN 00795879 Manufacturer: Eli Lilly Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 1997-12-11 · brand HUMULIN 30/70 (INSULIN HUMAN BIOSYNTH INJ) · ATC A10AD01 INSULIN (HUMAN) · form Suspension · route Subcutaneous · ingredients INSULIN 30 UNIT/ML, INSULIN ISOPHANE (NPH) 70 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Humulin 30/70: Formulary list price $29.9800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $29.9800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9788 · Verify on the e-Formulary ↗ (DIN 00795879)

Source record
DIN 00795879: Humulin 30/70 Raw flags: insOH=Y, sec3=Y Item: 682016009; group id 785; item number 1909; lccId None; manufacturer id LIL Source form: Inj Susp-10mL Pk; strength: 1000U/10mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $29.9800; ministry $29.9800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00795879 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9788
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:20:16 Insulins (Pre-Mixed)) and how they are covered

Matched class: 68:20:16 Insulins (Pre-Mixed)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN LISPRO & INSULIN LISPRO PROTAMINE 68:20:16 Insulins (Pre-Mixed)

INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Susp-10mL Pk, Inj Susp-5x3mL Pk

INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%

· 1 products · General benefit · strengths: 100U/mL · Inj Susp-5x3mL Pk

INSULIN LISPRO & INSULIN LISPRO PROTAMINE

· 4 products · General benefit · strengths: 25% & 75%, 50% & 50% · Inj Susp-5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:16
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: insulin requiring diabetic patients
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN) INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN) · General benefit INDICATIONS AND CLINICAL USE HUMULIN (insulin, human biosynthetic) is indicated for the treatment of insulin requiring diabetic patients. PM: https://pdf.hres.ca/dpd_pm/00060544.PDF; date March 26, 2021; DIN 00587737; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE HUMULIN (insulin, human biosynthetic) is indicated for the treatment of insulin requiring diabetic patients. HUMULIN-R only should be used for the treatment of emergencies such as diabetic coma and pre-coma and in diabetics undergoing surgery, but not HUMULIN-N, or HUMULIN MIXTURES. In switching patients from animal source insulins to HUMULIN, it is possible that the patients will require a change in dosage; the adjustment may be made with the first dose or over a period of several weeks. Any change of insulin should be made cautiously and only under medical supervision. Changes in refinement, purity, strength, brand, type and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dosage. HUMULIN Product Monograph Page 3 of 54 https://pdf.hres.ca/dpd_pm/00060544.PDF PM date: March 26, 2021 Source product: HUMULIN 30/70 (INSULIN HUMAN BIOSYNTH INJ); DIN 00795879; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.